145 related articles for article (PubMed ID: 35104581)
1. Translatome changes in acute myeloid leukemia cells post exposure to pegcrisantaspase and venetoclax.
Kapadia B; Shetty AC; Bollino D; Bhandary B; Lapidus RG; Mahmood K; Mahurkar A; Gartenhaus RB; Eckert RL; Emadi A
Exp Hematol; 2022 Apr; 108():55-63. PubMed ID: 35104581
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
3. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
4.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
7. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
8. [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):161-167. PubMed ID: 38418191
[No Abstract] [Full Text] [Related]
9. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
10. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
11. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
12. Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes.
Zhang S; Lou S; Bian W; Liu J; Wang R; Wang Y; Zhao Y; Zou X; Jin D; Liang Y; Sun J; Liu L
Biochem Biophys Res Commun; 2024 Jul; 719():150117. PubMed ID: 38761635
[TBL] [Abstract][Full Text] [Related]
13. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Mei M; Aldoss I; Marcucci G; Pullarkat V
Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
17. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q; Riley-Gillis B; Han L; Jia Y; Lodi A; Zhang H; Ganesan S; Pan R; Konoplev SN; Sweeney SR; Ryan JA; Jitkova Y; Dunner K; Grosskurth SE; Vijay P; Ghosh S; Lu C; Ma W; Kurtz S; Ruvolo VR; Ma H; Weng CC; Ramage CL; Baran N; Shi C; Cai T; Davis RE; Battula VL; Mi Y; Wang J; DiNardo CD; Andreeff M; Tyner JW; Schimmer A; Letai A; Padua RA; Bueso-Ramos CE; Tiziani S; Leverson J; Popovic R; Konopleva M
Signal Transduct Target Ther; 2022 Feb; 7(1):51. PubMed ID: 35185150
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
Waclawiczek A; Leppä AM; Renders S; Stumpf K; Reyneri C; Betz B; Janssen M; Shahswar R; Donato E; Karpova D; Thiel V; Unglaub JM; Grabowski S; Gryzik S; Vierbaum L; Schlenk RF; Röllig C; Hundemer M; Pabst C; Heuser M; Raffel S; Müller-Tidow C; Sauer T; Trumpp A
Cancer Discov; 2023 Jun; 13(6):1408-1427. PubMed ID: 36892565
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
[TBL] [Abstract][Full Text] [Related]
20. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients.
Zong L; Yin M; Kong J; Zhang J; Song B; Zhu J; Xue S; Wu X; Wu D; Bao X; Qiu H
Mol Carcinog; 2023 Oct; 62(10):1572-1584. PubMed ID: 37555764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
